Neurocrine Biosciences Inc (STU:NB3)
€ 153.15 -1.9 (-1.23%) Market Cap: 15.37 Bil Enterprise Value: 14.57 Bil PE Ratio: 26.83 PB Ratio: 5.14 GF Score: 93/100

Q1 2026 Neurocrine Biosciences Inc Earnings Call Transcript

May 05, 2026 / 08:30PM GMT
Release Date Price: €115.25 (+0.79%)
Operator

Hello, and welcome, everyone joining today's Neurocrine Biosciences Q1 2026 earnings call. (Operator Instructions) Please note, this call is being recorded. We are standing by if you should need any assistance.

It is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Todd Tushla
Neurocrine Biosciences Inc - Investor Relations

Thank you, and happy Cinco to mile to everyone. Welcome to Neurocrine Biosciences first quarter 2026 earnings call. Joining me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Sanjay Keswani, Chief Medical Officer; and Samir Sadanti, Vice President of Strategy and Corporate Development.

During today's call, we will be making forward-looking statements, including statements containing projections regarding future events such as the anticipated closing of our acquisition of Sileno Therapeutics. These statements are subject to certain risks and uncertainties, and our actual results may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot